AAAnil K. Agarwal

Anil K. Agarwal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anil K. Agarwal has a total of 227 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Capacity for the management of kidney failure in the International Society of Nephrology North America and the Caribbean region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)

    by Racquel Lowe-Jones, Isabelle Ethier, Lori-Ann Fisher, Michelle M.Y. Wong, Stephanie Thompson, Georges Nakhoul, Shaifali Sandal, Rahul Chanchlani, Sara N. Davison, Anukul Ghimire, et al.


  • Capacity for the management of kidney failure in the International Society of Nephrology South Asia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)

    by Eranga Wijewickrama, Muhammad Rafiqul Alam, Divya Bajpai, Smita Divyaveer, Arpana Iyengar, Vivek Kumar, Ahad Qayyum, Shankar Prasad Yadav, Manjusha Yadla, Silvia Arruebo, et al.


  • Effect of Intensive Blood Pressure Control on Kidney Outcomes

    by Paul E. Drawz, Kristin M. Lenoir, Nayanjot Kaur Rai, Anjay Rastogi, Chi D. Chu, Frederic F. Rahbari-Oskoui, Paul K. Whelton, George Thomas, Andrew McWilliams, Anil K. Agarwal, et al.

    Background: Intensive BP lowering in the Systolic Blood Pressure Intervention Trial (SPRINT) produced acute decreases in kidney function and higher risk for AKI. We evaluated the effect of intensive BP lowering on long-term changes in kidney function using trial and outpatient electronic health record (EHR) creatinine values. Methods: SPRINT data were linked with EHR data from 49 (of 102) study sites. The primary outcome was the total slope of decline in eGFR for the intervention phase and the post-trial slope of decline during the observation phase using trial and outpatient EHR values. Secondary outcomes included a ≥30% decline in eGFR to 2 and a ≥50% decline in eGFR or kidney failure among participants with baseline eGFR ≥60 and 2, respectively. Results: EHR creatinine values were available for a median of 8.3 years for 3041 participants. The total slope of decline in eGFR during the intervention phase was −0.67 ml/min per 1.73 m2 per year (95% confidence interval [CI], −0.79 to −0.56) in the standard treatment group and −0.96 ml/min per 1.73 m2 per year (95% CI, −1.08 to −0.85) in the intensive treatment group (P < 0.001). The slopes were not significantly different during the observation phase: −1.02 ml/min per 1.73 m2 per year (95% CI, −1.24 to −0.81) in the standard group and −0.85 ml/min per 1.73 m2 per year (95% CI, −1.07 to −0.64) in the intensive group. Among participants without CKD at baseline, intensive treatment was associated with higher risk of a ≥30% decline in eGFR during the intervention (hazard ratio, 3.27; 95% CI, 2.43 to 4.40), but not during the postintervention observation phase. In those with CKD at baseline, intensive treatment was associated with a higher hazard of eGFR decline only during the intervention phase (hazard ratio, 1.95; 95% CI, 1.03 to 3.70). Conclusions: Intensive BP lowering was associated with a steeper total slope of decline in eGFR and higher risk for kidney events during the intervention phase of the trial, but not during the postintervention observation phase.


  • Open Access

    Taurolidine/Heparin Lock Solution and Catheter-Related Bloodstream Infection in Hemodialysis

    by Anil K. Agarwal, Prabir Roy-Chaudhury, Phoebe Mounts, Elizabeth Hurlburt, Antony Pfaffle, Eugene C. Poggio

    Background: Catheter‐related bloodstream infections (CRBSIs) are one of the most prevalent, fatal, and costly complications of hemodialysis with a central venous catheter (CVC). The LOCK IT-100 trial compared the efficacy and safety of a taurolidine/heparin catheter lock solution that combines taurolidine 13.5 mg/ml and heparin (1000 units/ml) versus heparin in preventing CRBSIs in participants receiving hemodialysis via CVC. Methods: LOCK IT-100 was a randomized, double-blind, active-control, multicenter, phase 3 study that enrolled adults with kidney failure undergoing maintenance hemodialysis via CVC from 70 US sites. Participants were randomized 1:1 to taurolidine/heparin catheter lock solution or heparin control catheter lock solution (1000 units/ml). The primary end point was time to CRBSI as assessed by a blinded Clinical Adjudication Committee. Secondary end points were catheter removal for any reason and loss of catheter patency. On the basis of a prespecified interim analysis, the Data and Safety Monitoring Board recommended terminating the trial early for efficacy with no safety concerns. Results: In the full analysis population (N=795), nine participants in the taurolidine/heparin arm (n=397; 2%) and 32 participants in the heparin arm (n=398; 8%) had a CRBSI. Event rates per 1000 catheter days were 0.13 and 0.46, respectively, with the difference in time to CRBSI being statistically significant, favoring taurolidine/heparin (P < 0.001). The hazard ratio was 0.29 (95% confidence interval, 0.14 to 0.62), corresponding to a 71% reduction in risk of CRBSIs with taurolidine/heparin versus heparin. There were no significant differences between study arms in time to catheter removal for any reason or loss of catheter patency. The safety of taurolidine/heparin was comparable with that of heparin, and most treatment-emergent adverse events were mild or moderate. Conclusions: Taurolidine/heparin reduced the risk of developing a CRBSI in study participants receiving hemodialysis via CVC compared with heparin with a comparable safety profile. Clinical Trial registry name and registration number: Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection, NCT02651428.


  • Global challenges with providing vascular access care during COVID era

    by Karthik Ramani, Tushar J Vachharajani, Edgar Lerma, Anil K Agarwal

    Background: The COVID-19 pandemic has adversely affected health care systems and dialysis access care in the US and across the globe. Beyond the initial challenges posed by the pandemic and despite the actions taken by health care leaders/organizations/professional societies such as the “Maintaining Lifelines for ESKD Patients” joint statement, there continues to be delays in providing timely care and performing elective and emergent dialysis access procedures worldwide. The aim of this study was to assess the global challenges associated with providing dialysis vascular access care across the international vascular access community during the pandemic. Methods: The American Society of Diagnostic and Interventional Nephrology (ASDIN) conducted an online survey in 2021, that was administered to an expert panel of dialysis vascular access specialists and global leaders spanning across the international community. The respondents who are members of ASDIN, Association of Vascular Access and InTerventionAl Renal physicians (AVATAR), Asia Pacific Society of Dialysis Access (APSDA), Peruvian Vascular Access Society (APDAV), and Australia/New Zealand Society of Interventional Nephrology (ANZSIN) reported their experiences in the care of dialysis vascular access, practice patterns, and challenges faced during the COVID pandemic. Results: Of the 53 individual surveys sent, 16 were opened and 11 (69%) responses were received from across the world and from different practice settings. The survey revealed the continued challenges facing the international community, the stark disparities in care delivery, supply chain disruption and logistical, regulatory, and financial issues that the global community continues to face in the ongoing pandemic. Conclusions: The COVID19 pandemic is far from over, and the challenges and barriers to providing dialysis access care seen on the initial ASDIN survey in the US seem to extend across the globe. We describe those results and discuss options, opportunities, and innovative tools to provide dialysis and access care during these trying times.

  • Open Access

    A study of the Mental health assessment among COVID 19 patients

    by Anil K. Agarwal, Surendra Kumar Mahore, Rakesh Kumar Mahore, Ramniwas Mahore, Nishant Gupta

    Background: People's mental health has been impacted by the novel corona virus COVID 19. According to studies, a significant percentage of people who have recovered from the infection have mental health problems. The research was carried out on people who had recovered from COVID 19 in the previous year. Participants were contacted a month after being discharged from the hospital and encouraged to complete a questionnaire that included the DASS and IES scales. Anxiety, depression, stress, and post-traumatic stress disorder were all examined in the results (PTSD). Those with scores that indicated severe levels were encouraged to see a psychiatrist for proper treatment and therapy. The results of the DASS revealed that 2.5 percent of the participants had scores indicative of severe stress, 25.3 percent had scores indicative of severe anxiety, and 7.3 percent had scores indicative of severe depression. According to the results of the IES, 15.1 percent of the participants said the event had a significant impact on their mental health, and 17.2 percent of the participants had scores that indicated the presence of post-traumatic stress disorder symptoms. There is a strong link between IES scores and the severity of lung involvement.

  • Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study

    by Paul E. Drawz, Nayanjot Kaur Rai, Kristin Macfarlane Lenoir, Maritza Suarez, James R. Powell, Dominic S. Raj, Srinivasan Beddhu, Anil K. Agarwal, Sandeep Soman, Paul K. Whelton, et al.

    Key Points: Identifying ways to prevent AKI may reduce mortality further in the setting of intensive BP control. Creatinine-based ascertainment of AKI, enabled by electronic health record data, may be more sensitive and less biased than traditional serious adverse event adjudication. Background: Adjudication of inpatient AKI in the Systolic Blood Pressure Intervention Trial (SPRINT) was based on billing codes and admission and discharge notes. The purpose of this study was to evaluate the effect of intensive versus standard BP control on creatinine-based inpatient and outpatient AKI, and whether AKI was associated with cardiovascular disease (CVD) and mortality. Methods: We linked electronic health record (EHR) data from 47 clinic sites with trial data to enable creatinine-based adjudication of AKI. Cox regression was used to evaluate the effect of intensive BP control on the incidence of AKI, and the relationship between incident AKI and CVD and all-cause mortality. Results: A total of 3644 participants had linked EHR data. A greater number of inpatient AKI events were identified using EHR data (187 on intensive versus 155 on standard treatment) as compared with serious adverse event (SAE) adjudication in the trial (95 on intensive versus 61 on standard treatment). Intensive treatment increased risk for SPRINT-adjudicated inpatient AKI (HR, 1.51; 95% CI, 1.09 to 2.08) and for creatinine-based outpatient AKI (HR, 1.40; 95% CI, 1.15 to 1.70), but not for creatinine-based inpatient AKI (HR, 1.20; 95% CI, 0.97 to 1.48). Irrespective of the definition (SAE or creatinine based), AKI was associated with increased risk for all-cause mortality, but only creatinine-based inpatient AKI was associated with increased risk for CVD. Conclusions: Creatinine-based ascertainment of AKI, enabled by EHR data, may be more sensitive and less biased than traditional SAE adjudication. Identifying ways to prevent AKI may reduce mortality further in the setting of intensive BP control.


  • Approach to Arteriovenous Access

    by Nabil J. Haddad, Khaled Y. Boubes, Anil K. Agarwal

  • Approach to a Patient with Non-maturing AV Fistula

    by Khaled Y. Boubes, Nabil J. Haddad, Anil K. Agarwal

  • Lessons learnt and future directions in managing dialysis access during the COVID 19 pandemic: Patient and provider experience in the United States

    by Anil K Agarwal, Adrian Sequeira, Bharvi P Oza-Gajera, Karthik Ramani, Jeffrey Packer, Terry Litchfield, Mary Lea Nations, Edgar V Lerma

    Background: The COVID 19 pandemic adversely impacted delivery of preventive, routine, urgent, and essential care worldwide. Dialysis access care was particularly affected due to the lack of specific guidelines regarding procedures for its creation and maintenance. Early guidance by Centers for Medicare and Medicaid was inadvertently interpreted as guidance to stop dialysis access procedures. Prompt action by professional societies was needed to furnish detailed guidance to establish essential nature of these procedures. Methods: The American Society of Diagnostic and Interventional Nephrology (ASDIN) issued a joint statement with Vascular Access Society of the Americas (VASA) – “Maintaining Lifelines for ESKD Patients” to clearly establish the role of vascular access as a lifeline for ESKD (End Stage Kidney Disease) patients and the importance and urgency of its timely management. ASDIN also conducted a survey in mid-2020, that was administered to the ASDIN database as well as shared with the general public via the organization’s social media platforms. The respondents reported their experiences in the care of dialysis access, practice patterns and the utility of the ASDIN-VASA statement during the COVID 19 pandemic. Results: Of the 2030 individual surveys sent, 581 were opened and 53 (9.1%) responses were received from different parts of the country and from different practice settings. ASDIN COVID 19 triage document was frequently utilized and 83% of respondents found the document valuable. The survey also revealed multiple obstacles, including logistical and financial issues that led to significant disruption of services. Conclusions: The care of dialysis access was significantly affected in the United States during the COVID 19 pandemic due to multiple reasons. ASDIN actions provided valuable specific guidance regarding and explored barriers to dialysis access care. We describe those results and discuss strategies to prevent COVID 19 transmission with innovative strategies of providing access care. Individualized decision making is of essence when considering dialysis access procedures.